Major Medical Centers ask Congress to Probe Genentech Distribution Shift - Pharmalot - WSJ

• Register to take a Board-approved California Designated Representative training course for:
          Wholesalers | 3PL | Reverse Distributors

Read the full article: Major Medical Centers ask Congress to Probe Genentech Distribution Shift - Pharmalot - WSJ:

"Last month, Genentech angered hospitals and academic medical centers around the country by changing distribution for three big-selling cancer medicines. The drug maker is now using a handful of specialty distributors, which are actually divisions of the same wholesalers that have already been distributing Avastin, Rituxan and Herceptin. Until recently, dozens of wholesalers stocked the drugs."

'via Blog this'

Return Home:  The Designated Representative and Exemptee Blog

- - -

For Designated Representative license applicants  -  Training programs, courses, classes, seminars:

     California (earn a training affidavit):

• CA Designated Representative Wholesaler Training - Available around-the-clock 24 x 7
• CA Designated Representative 3PL Training
• CA Designated Representative Reverse Distributor Training  
• The Designated Representative Institute

     Florida:

• Florida Certified Designated Representative - CDR Laws and Rules Examination Prep Course

For HMDR Exemptee license applicants  -  Training programs, courses, classes, seminars:

     California (earn a training completion certificate):

• CA Home Medical Device Retailer (HMDR) Exemptee Training Course
• The Exemptee Institute

Genentech's distribution change for cancer drugs upsets hospitals | Modern Healthcare

Read the full article: Genentech's distribution change for cancer drugs upsets hospitals | Modern Healthcare:

"Drugmaker Genentech is changing the way it ships three high-profile cancer drugs to hospitals, which are concerned that the new process will grossly inflate their already high costs and potentially affect patient care. Genentech contends the change is designed to ensure patient safety and access to the drugs involved.

In a Sept. 16 letter to hospital pharmacy directors (PDF), Genentech, a U.S. subsidiary of Swiss healthcare giant Roche, said effective Oct. 1, hospitals can receive Avastin, Herceptin and Rituxan only through six authorized specialty distributors. The approved companies are ASD Healthcare, BioSolutionsDirect, Cardinal Health Specialty Distribution, McKesson Plasma and Biologics, Morris & Dickson Specialty Distribution and Smith Medical Partners.

For hospitals, this means they will have to contract with one of those specialty distributors if they want to continue receiving those three cancer drugs. Previously, hospitals purchased the drugs through wholesale distributors, which offer hospitals discounts based on purchase volume."

'via Blog this'

Return Home:  The Designated Representative and Exemptee Blog